Functional genomics applications and therapeutic implications in sarcopenia

Mutat Res Rev Mutat Res. 2019 Jul-Sep:781:175-185. doi: 10.1016/j.mrrev.2019.04.003. Epub 2019 Apr 20.

Abstract

The human genome contains around 20,000-25,000 genes coding for 30,000 proteins. Some proteins and genes represent therapeutic targets for human diseases. RNA and protein expression profiling tools allow the study of the molecular basis of aging and drug discovery validation. Throughout the life, there is an age-related and disease-related muscle decline. Sarcopenia is defined as a loss of muscle mass and a decrease in functional properties such as muscle strength and physical performance. Yet, there is still no consensus on the evaluation methods of sarcopenia prognosis. The main challenge of this complex biological phenomena is its multifactorial etiology. Thus, functional genomics methods attempt to shape the related scientific approaches via an innovative in-depth view on sarcopenia. Gene and drug high throughput screening combined with functional genomics allow the generation and the interpretation of a large amount of data related to sarcopenia and therapeutic progress. This review focuses on the application of selected functional genomics techniques such as RNA interference, RNA silencing, proteomics, transgenic mice, metabolomics, genomics, and epigenomics to better understand sarcopenia mechanisms.

Keywords: Epigenomics; Functional genomics; Genomics; Metabolomics; Proteomics; RNA silencing; Sarcopenia; Trangenic mice.

Publication types

  • Review

MeSH terms

  • Animals
  • Epigenomics / methods
  • Gene Expression
  • Genomics / methods
  • Humans
  • Metabolomics / methods
  • Muscle Strength / genetics
  • Prognosis
  • Proteomics / methods
  • Sarcopenia / genetics*
  • Sarcopenia / pathology